INdustrycTceh INsight Logo

J&J lowered its revenue and earnings expectations for 2022

J&J lowered its revenue and earnings expectations for 2022

April 20, 2022: On Tuesday, Johnson & Johnson ( J&J ) lowered its full-year sales and earnings outlook and stopped providing Covid-19 vaccine revenue guidance because of a global supply surplus and demand uncertainty.

J&J forecasts sales of $94.8 billion to $95.8 billion, about $1 billion less than the guidance provided in January. The company lowered its adjusted earnings per share by 25 cents to $10.15 and $10.35 for the whole year, from the last forecast of $10.40 to $10.60.

J&J reported first-quarter sales of $23.4 billion, slightly missing Wall Street expectations but growing 5% over the same quarter last year. The company posted earnings of 2.67 cents per share, beating expectations and increasing 3.1% over the same period of 2021. J&J reported a net income of $5.15 billion, a nearly 17% decrease over the first quarter of 2021.

CFO Joe Wolk said Tuesday that developing nations have limited capacity in terms of refrigeration and getting shots in arms, which has created a backlog of vaccines. The company sold $457 million of its Covid vaccine globally. When asked about no longer providing a sales outlook for the photos, Wolk said it was unusual to guide a specific product, to begin with.

“We did it last year because we understood the Street had an expectation or at least an excitement around understanding how vaccine sales might play out, but it was never material,” Wolk told CNBC’s Meg Tirrell on “Squawk Box,” noting the vaccine is not for profit and doesn’t impact the company’s bottom line. He said Covid vaccine sales met J&J’s internal expectations.

J&J reported $12.87 billion in pharmaceutical sales, a raise of 6.3% over the same quarter in the previous year. The company’s medical devices business grew by 5.9% to $6.97 billion in sales compared with the first quarter of 2021. Sales at J&J’s consumer health business, which it is spinning off into a separate publicly-traded company, declined 1.5% to $3.59 billion.

In pharmaceuticals, Wolk said recent prescriptions slowed in early January when the Covid omicron variant swept the U.S. but picked up in February and March. He said J&J’s medical devices business led the company’s growth with an uptick in general and advanced surgery and orthopedics. The company’s medical devices segment has struggled during Covid increases when elective procedures are delayed because hospitals are overwhelmed with sick patients with the virus.

About Us

We provide the insights on leaders who are responsible for taking their organization to new heights, all the while bringing together a group of talented individuals.

Recent Posts

J&J lowered its revenue and earnings expectations for 2022